Tvardi Therapeutics (TVRD) EBIT: 2013-2017
Historic EBIT for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to -$13.0 million.
- Tvardi Therapeutics' EBIT fell 10.05% to -$13.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was -$67.2 million, marking a year-over-year decrease of 46.74%. This contributed to the annual value of -$58.4 million for FY2016, which is 131.86% down from last year.
- Latest data reveals that Tvardi Therapeutics reported EBIT of -$13.0 million as of Q3 2017, which was down 34.50% from -$9.6 million recorded in Q2 2017.
- In the past 5 years, Tvardi Therapeutics' EBIT registered a high of $6.9 million during Q2 2013, and its lowest value of -$22.3 million during Q1 2017.
- Moreover, its 3-year median value for EBIT was -$11.0 million (2016), whereas its average is -$11.7 million.
- Per our database at Business Quant, Tvardi Therapeutics' EBIT tumbled by 153.65% in 2014 and then increased by 27.71% in 2017.
- Over the past 5 years, Tvardi Therapeutics' EBIT (Quarterly) stood at -$2.1 million in 2013, then crashed by 105.99% to -$4.3 million in 2014, then plummeted by 124.38% to -$9.7 million in 2015, then crashed by 129.37% to -$22.3 million in 2016, then fell by 10.05% to -$13.0 million in 2017.
- Its EBIT stands at -$13.0 million for Q3 2017, versus -$9.6 million for Q2 2017 and -$22.3 million for Q1 2017.